Gut microbiome drug discovery and FMT therapeutic development
Metagen Therapeutics is a microbiome-focused drug discovery company built on Metabologenomics research, now executing across clinical trial design, regulatory pathways, and FMT platform implementation. The stack reveals an early-stage biotech operational footprint—AWS infrastructure, Python for biodata work, Zoho CRM for partnership pipeline—with pain points centered on donor supply chain, clinical trial complexity for novel therapies, and multi-site scaling. Hiring shows broad functional gaps (ops, research, engineering, manufacturing all under-resourced) typical of a discovery-stage firm transitioning toward clinical and commercial phases.
Notable leadership hires: CMC Project Lead
Metagen Therapeutics discovers and develops therapeutics based on gut microbiome science, with a focus on fecal microbiota transplantation (FMT) and associated bioactive compounds. Founded in 2020 and based in Tsuruoka, Japan, the company is actively pursuing clinical trials (ulcerative colitis indication visible in project list), regulatory submissions, manufacturing capability, and supply-chain setup for donor-derived materials. The team spans research, engineering, operations, and manufacturing functions across 11–50 employees. They seek partnerships across pharma, healthcare, functional foods, and academic institutions.
Primary focus: FMT drug development, clinical trials in ulcerative colitis, CMC (chemistry, manufacturing, controls) strategy, regulatory submissions, and a proprietary FMT implementation platform. Secondary: biodata informatics research and donor system management.
Headquartered in Tsuruoka, Yamagata, Japan. All current hiring is in Japan. Founded in 2020.
AWS (compute/Lambda/ECS), Python, BigQuery, Vue/Nuxt frontend, Zoho CRM, GitHub, and standard Google/Microsoft productivity suites. Stack reflects a clinical-stage biotech with lean engineering and data infrastructure.
Other companies in the same industry, closest in size